TICKERNERD
Menu
VKTXVKTXHealthcare · Biotechnology

VKTX Stock Forecast: Viking Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$34
−1.40% on the day

The 20 Wall Street analysts covering Viking Therapeutics, Inc. hold a median 12-month price target of $95 — +180.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 21 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.0B
Ticker Nerd rank
34 / 100
Median analyst target
$95
Analysts covering
20
Total return, dividends reinvested
1W
+2.1%
1M
−10.7%
YTD
−3.7%
1Y
+32.0%
From 52W high
−19.6%
From 52W low
+46.7%
$23
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VKTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viking Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Value
70
Volatility
66
Revisions
54
Momentum
48
Issuance
33
Size
27
Quality
27
Growth
19

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VKTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VKTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26VKTXHigh $125Median $95Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says20 analysts
18 Buy2 Hold0 Sell
Low $35Median $95High $125

The green dot is the last close — the median target sits +180.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026JP MorganMaintainsOverweight$75 → $65
30 July 2026Canaccord GenuityMaintainsBuy$107 → $114
30 July 2026Canaccord GenuityMaintainsBuy—
28 May 2026Lake StreetInitiatesBuy$89
28 May 2026Lake StreetInitiatesBuy—
1 May 2026BTIGReiteratesBuy—
30 Apr 2026Cantor FitzgeraldMaintainsOverweight—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
12 Nov 2025Canaccord GenuityMaintainsBuy—
29 Oct 2025Canaccord GenuityInitiatesBuy—
24 Oct 2025JP MorganMaintainsOverweight—
23 Oct 2025Morgan StanleyMaintainsOverweight—
29 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Sept 2025BTIGReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
24 July 2025CitigroupMaintainsNeutral—
24 July 2025Raymond JamesMaintainsStrong Buy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025Cantor FitzgeraldInitiatesOverweight—
28 Apr 2025Truist SecuritiesReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VKTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VKTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
4
Fundamentals

Viking Therapeutics, Inc. (VKTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.6×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
9.7×

Cheaper than 11% of US stocks

EV / EBITDA
−8.9×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 14% of US stocks

Return on assets
−51.9%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VKTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VKTXViking Therapeutics, Inc.$4.0B
34
DNLIDenali Therapeutics, Inc.$3.9B
64
TNGXTango Therapeutics, Inc.$3.9B
41
RCUSArcus Biosciences, Inc.$3.8B
58
IDYAIDEAYA Biosciences, Inc.$3.7B
83
IOVAIovance Biotherapeutics, Inc.$3.7B
88
RLAYRelay Therapeutics, Inc.$4.2B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viking Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VKTX news & analysis

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Zacks Investment Research · 17 Aug 2026neutral

Zacks reported that Eli Lilly's strong Q2 results, GLP-1 momentum, and broad pipeline support growth, though valuation and rising competition remain key risks. The article discusses whether the stock is a buy, sell, or hold.

Why it matters — A VKTX watcher would care because Lilly is a major player in the GLP-1 space, and competitive dynamics in that market can affect Viking's prospects.

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

The Motley Fool · 8 Aug 2026positive

The Motley Fool compares Eli Lilly and Viking Therapeutics as GLP-1 stocks, noting that Eli Lilly leads the GLP-1 market and could stay ahead due to its deep pipeline. The article also states that Viking Therapeutics' leading GLP-1 candidate looks promising.

Why it matters — VKTX watchers would care because the piece highlights the promise of the company's leading GLP-1 candidate amid competitive market positioning.

Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview)

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha maintained a Hold rating on Viking Therapeutics, citing intensifying competition in the GLP-1 obesity drug space and noting that a key catalyst—the maintenance dosing study for lead asset VK2735—is due in Q3.

Why it matters — A VKTX watcher would care because the upcoming VK2735 maintenance dosing study results could drive price volatility and influence the company's funding needs amid high cash burn.

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

The Motley Fool · 6 Aug 2026positive

Viking Therapeutics' stock declined in July, with cash burn and potential dilution cited as key investor concerns. The company's phase 3 trials remain on track, and investors await results from a maintenance trial expected this quarter.

Why it matters — For VKTX watchers, the July decline reflects near-term financing worries, but on-track phase 3 trials and the upcoming maintenance trial results leave the company's long-term prospects unchanged.

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

The Motley Fool · 30 July 2026neutral

The Motley Fool suggests Viking Therapeutics could be a prime acquisition target for large pharmaceutical companies, citing its pipeline in weight management as a key factor. The article notes the company's prospects appear promising but carry significant risk.

Why it matters — VKTX watchers would care because the piece positions the company as a potential big pharma takeover candidate in the weight-management space, which could influence how investors view the stock's long-term outlook.

FAQ

Frequently asked questions about VKTX stock

What is the VKTX stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Viking Therapeutics, Inc. have a median 12-month price target of $95, with estimates ranging from $35 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VKTX stock a buy right now?

Of the 20 analysts covering Viking Therapeutics, Inc., 18 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viking Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VKTX?

As at 21 Aug 2026, Viking Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will VKTX stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +180.4% from the last close, and Ticker Nerd's factor model ranks Viking Therapeutics, Inc. 34 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VKTX stock forecast for 2030?

No analyst covering Viking Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VKTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $125 over the next 12 months.

How has VKTX stock performed over the past year?

Viking Therapeutics, Inc. returned +32.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viking Therapeutics, Inc. do?

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

What is the latest news on VKTX?

The most recent item we track (Zacks Investment Research, 17 Aug 2026): "LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?". Zacks reported that Eli Lilly's strong Q2 results, GLP-1 momentum, and broad pipeline support growth, though valuation and rising competition remain key risks. The article discusses whether the stock is a buy, sell, or hold.

Company

About Viking Therapeutics, Inc.

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, Viking concentrates on mechanism-driven drug candidates targeting obesity, metabolic liver disease, and rare genetic conditions. Its lead program, VK2735, is being advanced in both subcutaneous and oral formulations as a dual agonist of GLP-1 and GIP receptors for the potential treatment of obesity and related metabolic disorders. Viking also develops VK2809, a selective thyroid hormone receptor beta agonist aimed at lipid and broader metabolic disorders, and VK0214, a similar class molecule targeting X-linked adrenoleukodystrophy, a rare neuro-metabolic disease. In addition, the company is progressing internally developed dual amylin and calcitonin receptor agonists for obesity and other metabolic conditions. Operating as a single business segment centered on research and clinical development, Viking Therapeutics plays a specialized role in the healthcare and biotechnology market by supplying a focused pipeline of metabolic and endocrine drug candidates to address areas of significant unmet medical need.

CEO Dr. Brian Lian Ph.D. · 65 employees · United States · https://www.vikingtherapeutics.com